Acetamides

Global Oxiracetam (CAS 62613-82-5) Market Report 2020: Market Overview, Manufacturers and Distributors, Prices, End-Users and Downstream Industry Trends

Retrieved on: 
Wednesday, August 12, 2020
Psychoactive drugs, Acetamides, Oxiracetam, Racetams, Stimulants, Chemical compounds, Market research

DUBLIN, Aug. 12, 2020 /PRNewswire/ -- The "Oxiracetam (CAS 62613-82-5) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 12, 2020 /PRNewswire/ -- The "Oxiracetam (CAS 62613-82-5) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Oxiracetam.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The Oxiracetam global market report key points:

Global Oxiracetam (CAS 62613-82-5) Market Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 10, 2020
Health, Pharmaceutical, Psychoactive drugs, Acetamides, Oxiracetam, Racetams, Stimulants, Chemical compounds, Market research

The "Oxiracetam (CAS 62613-82-5) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oxiracetam (CAS 62613-82-5) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Oxiracetam.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The Oxiracetam global market report key points:

2020 Global Tetraacetylethylenediamine Market: By Product, By Application, By End-Use, By Composition, By Region, Competition, Forecast & Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, July 31, 2020
Chemicals, Plastics, Manufacturing, Acetamides, Tetraacetylethylenediamine

The Global Tetraacetylethylenediamine Market is expected to grow at a substantial CAGR during the forecast period.

Key Points: 
  • The Global Tetraacetylethylenediamine Market is expected to grow at a substantial CAGR during the forecast period.
  • Increasing development of washing products is leading to increased use of TAED, which is a major factor boosting the growth of the tetraacetylethylenediamine market.
  • However, instability in the price of raw materials might hamper the growth of the Global Tetraacetylethylenediamine Market in the years to come.
  • To classify and forecast the Global Tetraacetylethylenediamine Market based on product, application, end-use, composition, company and regional distribution.

Fresenius Kabi Issues Voluntary Nationwide Recall of Two Lots of Dexmedetomidine Hydrochloride Injection Due to Cross-Contamination of Lidocaine

Retrieved on: 
Wednesday, July 22, 2020
FDA, Pharmaceutical, Health, Surgery, RTT, Drugs, Local anesthetics, Acetamides, Lidocaine, Medical specialties, Fresenius, Clinical medicine, FDA, Pharmaceutical, Health, Surgery, RTT, Drugs, Local anesthetics, Acetamides, Lidocaine, Medical specialties, Fresenius, Clinical medicine

Fresenius Kabi USA is voluntarily recalling two lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 mcg/50 mL (4 mcg / mL), 50 mL fill in a 50 mL vial.

Key Points: 
  • Fresenius Kabi USA is voluntarily recalling two lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 mcg/50 mL (4 mcg / mL), 50 mL fill in a 50 mL vial.
  • Fresenius Kabi initiated this recall due to the possibility of a trace amount of lidocaine present in these two lots and our investigation indicates that this issue is limited to these two product lots.
  • (Photo: Business Wire)
    To date, no adverse drug experience reports have been received for either of the lots being recalled by Fresenius Kabi.
  • Administration of Dexmedetomidine HCl containing trace amounts of lidocaine to a patient with lidocaine allergy, however, could result in anaphylaxis, a potentially life-threatening condition.

Dr. Reddy's Laboratories Announces the Launch of Colchicine Tablets USP, 0.6 mg in the U.S. Market

Retrieved on: 
Friday, June 12, 2020
Biotechnology, FDA, Pharmaceutical, Health, Articles, Organic compounds, Drugs, RTT, Acetamides, Alkaloids, Colchicine, Dr. Reddy's Laboratories, Generic drug, IQVIA

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Colchicine Tablets USP, a therapeutic equivalent generic version of Colcrys (colchicine) Tablets, 0.6 mg, approved by the U.S. Food and Drug Administration (USFDA).

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Colchicine Tablets USP, a therapeutic equivalent generic version of Colcrys (colchicine) Tablets, 0.6 mg, approved by the U.S. Food and Drug Administration (USFDA).
  • The Colcrys brand and generic market had U.S. sales of approximately $491 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health*.
  • Dr. Reddys Colchicine is available in 0.6 mg tablets in bottle count sizes of 30s and 100s.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Novadoz Pharmaceuticals FDA Approvals of Oseltamivir and Dofetilide Continues the Company's Rise in the Generic Market

Retrieved on: 
Thursday, June 4, 2020
Health, Articles, Neuraminidase inhibitors, Acetamides, Antivirals, Dofetilide, Sulfonamides, Oseltamivir, Generic drug, Genentech, Pharmaceutical industry, Food and Drug Administration

PISCATAWAY, N.J., June 4, 2020 /PRNewswire/ --Novadoz Pharmaceuticals, the U.S based sales & marketing affiliate for MSN Labs, located in Hyderabad India, recently received FDA approval for their generic versions of Oseltamivir Phosphate Capsules and Dofetilide Capsules.

Key Points: 
  • PISCATAWAY, N.J., June 4, 2020 /PRNewswire/ --Novadoz Pharmaceuticals, the U.S based sales & marketing affiliate for MSN Labs, located in Hyderabad India, recently received FDA approval for their generic versions of Oseltamivir Phosphate Capsules and Dofetilide Capsules.
  • Dofetilide is an antiarrhythmic drug used sustain a normal heart beat in patients with certain heart rhythm disorders of the atrium.
  • Most recently, Novadoz/MSN, received approval for Oseltamivir Phosphate 30mg, 40mg, and 75mg capsules, AB rated to Genentech Pharmaceuticals' Tamiflu.
  • Seshu Akula, Novadoz President North America Generics, states, "MSN's FDA approvals for generic Dofetilide and Oseltamivir capsules continues to demonstrate the strength of the organization's R&D capabilities.

TSRL, Inc. awarded $3M NIH grant to continue development of microneedle patch for treatment of influenza

Retrieved on: 
Thursday, May 28, 2020
Infectious diseases, Neuraminidase inhibitors, Medical specialties, Acetamides, Guanidines, Influenza, RTT, Zanamivir, Chemistry, Microneedle, Virus

The project builds on an initial Phase I Small Business Innovation Research (SBIR) award of $600,000 to optimize microneedle formulations for painless administration of zanamivir through the skin.

Key Points: 
  • The project builds on an initial Phase I Small Business Innovation Research (SBIR) award of $600,000 to optimize microneedle formulations for painless administration of zanamivir through the skin.
  • Influenza, or "the flu," is caused by RNA viruses.
  • It infects birds and mammals and spreads worldwide during seasonal epidemics that result in up to 500,000 deaths every year.
  • Microneedle patches allow for painless administration and can deliver zanamivir over multiple days with a single administration.

Montreal Heart Institute Colcorona Study receives grant from the COVID-19 Therapeutics Accelerator via the Bill & Melinda Gates Foundation to investigate cheap, readily available drug

Retrieved on: 
Tuesday, May 12, 2020
Computer security software, Organic compounds, Drugs, Acetamides, Alkaloids, Colchicine, RTT, MHI, Alwaleed Philanthropies, Montreal Heart Institute, Avast, Mark Zuckerberg

MONTREAL, May 12, 2020 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) Research Center today announced a 3-million-dollar grant from the COVID-19 Therapeutics Accelerator for its innovative ColCorona COVID-19 clinical trial.

Key Points: 
  • MONTREAL, May 12, 2020 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) Research Center today announced a 3-million-dollar grant from the COVID-19 Therapeutics Accelerator for its innovative ColCorona COVID-19 clinical trial.
  • The hypothesis is that colchicine may prevent the phenomenon of major inflammatory storm responsible for severe complications seen in patients with COVID-19.
  • This is one of the few current studies of COVID-19 infection in which non-hospitalized individuals can participate.
  • COVID-19 Therapeutics Accelerator donors include the Bill & Melinda Gates Foundation, Wellcome, Mastercard, U.K. Department for International Development, Chan Zuckerberg Initiative, Michael & Susan Dell Foundation, Avast, Zhang Yiming, Alwaleed Philanthropies, EQT and Madonna.

Influenza Treatment Market to Garner $1.22 Bn, Globally, by 2026 at 4.5% CAGR: Allied Market Research

Retrieved on: 
Wednesday, May 6, 2020
Infectious diseases, RTT, Viruses, Medicine, Neuraminidase inhibitors, Acetamides, Animal virology, Influenza A virus, Influenza, Oseltamivir

Increase in incidences of influenza across the globe, rise in healthcare expenditure worldwide, and rise in R&D investments for discovery of new drugs have boosted the growth of the global influenza treatment market.

Key Points: 
  • Increase in incidences of influenza across the globe, rise in healthcare expenditure worldwide, and rise in R&D investments for discovery of new drugs have boosted the growth of the global influenza treatment market.
  • Based on type, the oseltamivir phosphate segment held the largest share in 2018, accounting for more than two-fifths of the global influenza treatment market.
  • In addition, the same segment held the largest share in 2018, accounting for nearly half of the global influenza treatment market.
  • However, the global influenza treatment market across Asia-Pacific is estimated to portray the fastest CAGR of 5.6% during the forecast period.

Influenza Treatment Market to Garner $1.22 Bn, Globally, by 2026 at 4.5% CAGR: Allied Market Research

Retrieved on: 
Wednesday, May 6, 2020
Infectious diseases, RTT, Viruses, Medicine, Neuraminidase inhibitors, Acetamides, Animal virology, Influenza A virus, Influenza, Oseltamivir

Increase in incidences of influenza across the globe, rise in healthcare expenditure worldwide, and rise in R&D investments for discovery of new drugs have boosted the growth of the global influenza treatment market.

Key Points: 
  • Increase in incidences of influenza across the globe, rise in healthcare expenditure worldwide, and rise in R&D investments for discovery of new drugs have boosted the growth of the global influenza treatment market.
  • Based on type, the oseltamivir phosphate segment held the largest share in 2018, accounting for more than two-fifths of the global influenza treatment market.
  • In addition, the same segment held the largest share in 2018, accounting for nearly half of the global influenza treatment market.
  • However, the global influenza treatment market across Asia-Pacific is estimated to portray the fastest CAGR of 5.6% during the forecast period.